Growth Metrics

Castle Biosciences (CSTL) Accumulated Expenses (2018 - 2026)

Castle Biosciences' Accumulated Expenses history spans 8 years, with the latest figure at $38.3 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 17.61% to $38.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $38.3 million, a 17.61% increase, with the full-year FY2025 number at $38.3 million, up 17.61% from a year prior.
  • Accumulated Expenses hit $38.3 million in Q4 2025 for Castle Biosciences, up from $31.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CSTL hit a ceiling of $38.3 million in Q4 2025 and a floor of $5.2 million in Q1 2021.
  • Historically, Accumulated Expenses has averaged $20.0 million across 5 years, with a median of $18.7 million in 2022.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 90.75% in 2021 and later increased 12.47% in 2024.
  • Tracing CSTL's Accumulated Expenses over 5 years: stood at $15.5 million in 2021, then skyrocketed by 57.32% to $24.4 million in 2022, then increased by 18.83% to $28.9 million in 2023, then increased by 12.47% to $32.6 million in 2024, then increased by 17.61% to $38.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for CSTL at $38.3 million in Q4 2025, $31.8 million in Q3 2025, and $25.0 million in Q2 2025.